DOCSLIB.ORG

Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery 734 ASHP Therapeutic Guidelines Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery These guidelines were developed jointly by the American evidence base are noted within each individual procedure Society of Health-System Pharmacists (ASHP), the section of the guidelines. Published guidelines with recom- Infectious Diseases Society of America (IDSA), the Surgical mendations by experts in a procedure area (e.g., American Infection Society (SIS), and the Society for Healthcare College of Obstetricians and Gynecologists [ACOG]) and Epidemiology of America (SHEA). This work represents noted general guidelines (e.g., Centers for Disease Control an update to the previously published ASHP Therapeutic and Prevention [CDC], Scottish Intercollegiate Guidelines Guidelines on Antimicrobial Prophylaxis in Surgery,1 as well Network, Medical Letter, SIS, SHEA/IDSA) were also con- as guidelines from IDSA and SIS.2,3 The guidelines are in- sidered.2,3,5–11 tended to provide practitioners with a standardized approach Recommendations for the use of antimicrobial pro- to the rational, safe, and effective use of antimicrobial agents phylaxis are graded according to the strength of evidence for the prevention of surgical-site infections (SSIs) based on available. The strength of evidence represents only support currently available clinical evidence and emerging issues. for or against prophylaxis and does not apply to the antimi- Prophylaxis refers to the prevention of an infection crobial agent, dose, or dosage regimen. Studies supporting and can be characterized as primary prophylaxis, secondary the recommendations for the use of antimicrobial therapy prophylaxis, or eradication. Primary prophylaxis refers to were classified as follows: the prevention of an initial infection. Secondary prophylaxis refers to the prevention of recurrence or reactivation of a • Level I (evidence from large, well-conducted, ran- preexisting infection. Eradication refers to the elimination domized, controlled clinical trials or a meta-analysis) of a colonized organism to prevent the development of an • Level II (evidence from small, well-conducted, ran- infection. These guidelines focus on primary perioperative domized, controlled clinical trials) prophylaxis. • Level III (evidence from well-conducted cohort stud- ies) Guidelines Development and Use • Level IV (evidence from well-conducted case–control studies) Members of ASHP, IDSA, SIS, and SHEA were appointed • Level V (evidence from uncontrolled studies that were to serve on an expert panel established to ensure the valid- not well conducted) ity, reliability, and utility of the revised guidelines. The work • Level VI (conflicting evidence that tends to favor the of the panel was facilitated by faculty of the University of recommendation) Pittsburgh School of Pharmacy and University of Pittsburgh • Level VII (expert opinion or data extrapolated from Medical Center Drug Use and Disease State Management evidence for general principles and other procedures) Program who served as contract researchers and writers for the project. Panel members and contractors were required This system has been used by the Agency for to disclose any possible conflicts of interest before their ap- Healthcare Research and Quality, and ASHP, IDSA, SIS, pointment and throughout the guideline development pro- and SHEA support it as an acceptable method for organizing cess. Drafted documents for each surgical procedural section strength of evidence for a variety of therapeutic or diagnostic were reviewed by the expert panel and, once revised, were recommendations.4 Each recommendation was categorized available for public comment on the ASHP website. After ad- according to the strength of evidence that supports the use ditional revisions were made to address reviewer comments, or nonuse of antimicrobial prophylaxis as category A (levels the final document was approved by the expert panel and the I–III), category B (levels IV–VI), or category C (level VII). boards of directors of the above-named organizations. When higher-level data are not available, a category C recommendation represents a consensus of expert panel Strength of Evidence and Grading of Recommendations. members based on their clinical experience, extrapola- The primary literature from the previous ASHP Therapeutic tion from other procedures with similar microbial or other Guidelines on Antimicrobial Prophylaxis in Surgery1 was clinical features, and available published literature. In these reviewed together with the primary literature published be- cases, the expert panel also extrapolated general principles tween the date of the previous guidelines, 1999, and June and evidence from other procedures. Some recommenda- 2010, identified by searches of MEDLINE, EMBASE, and tions include alternative approaches in situations in which the Cochrane Database of Systematic Reviews. Particular panel member opinions were divided. attention was paid to study design, with greatest credence A major limitation of the available literature on anti- given to randomized, controlled, double-blind studies. microbial prophylaxis is the difficulty in establishing sig- There is a limited number of adequately powered random- nificant differences in efficacy between prophylactic antimi- ized controlled trials evaluating the efficacy of antimicrobial crobial agents and controls (including placebo, no treatment, prophylaxis in surgical procedures. Guidelines development or other antimicrobial agents) due to study design and low included consideration of the following characteristics: va- SSI rates for most procedures. A small sample size increases lidity, reliability, clinical applicability, flexibility, clarity, the likelihood of a Type II error; therefore, there may be no and a multidisciplinary nature as consistent with ASHP’s apparent difference between the antimicrobial agent and pla- philosophy on therapeutic guidelines.4 The limitations of the cebo when in fact the antimicrobial has a beneficial effect.12 ASHP Therapeutic Guidelines 735 A valid study is placebo controlled and randomized with a These guidelines reflect current knowledge of antimi- sufficient sample in each group to avoid a Type II error. Of crobial prophylaxis in surgery. Given the dynamic nature of note, prophylaxis is recommended in some cases due to the scientific information and technology, periodic review, up- severity of complications of postoperative infection (e.g., dating, and revisions are to be expected. an infected device that is not easily removable) necessitat- ing precautionary measures despite the lack of statistical Special Patient Populations. Pediatric patients. Pediatric support. patients undergo a number of procedures similar to adults that may warrant antimicrobial prophylaxis. Although pedi- Summary of Key Updates. These guidelines reflect sub- atric-specific prophylaxis data are sparse, available data have stantial changes from the guidelines published in 1999.1 been evaluated and are presented in some of the procedure- Highlights of those changes are outlined here. specific sections of these guidelines. Selection of antimi- Preoperative-dose timing. The optimal time for admin- crobial prophylactic agents mirrors that in adult guidelines, istration of preoperative doses is within 60 minutes before with the agents of choice being first- and second-generation surgical incision. This is a more-specific time frame than cephalosporins, reserving the use of vancomycin for patients the previously recommended time, which was “at induction with documented b-lactam allergies.19,20 While the use of a of anesthesia.” Some agents, such as fluoroquinolones and penicillin with a b-lactamase inhibitor in combination with vancomycin, require administration over one to two hours; cefazolin or vancomycin and gentamicin has also been stud- therefore, the administration of these agents should begin ied in pediatric patients, the number of patients included in within 120 minutes before surgical incision. these evaluations remains small.20–23 As with adults, there is Selection and dosing. Information is included regard- little evidence supporting the use of vancomycin, alone or ing the approach to weight-based dosing in obese patients in combination with other antimicrobials, for routine peri- and the need for repeat doses during prolonged proce- operative antimicrobial prophylaxis in institutions that have dures.13–18 Obesity has been linked to an increased risk for a high prevalence of methicillin-resistant Staphylococcus SSI. The pharmacokinetics of drugs may be altered in obese aureus (MRSA). Vancomycin may be considered in children patients, so dosage adjustments based on body weight may known to be colonized with MRSA and, in one retrospective be warranted in these patients. For all patients, intraopera- historical cohort study, was shown to decrease MRSA infec- tive redosing is needed to ensure adequate serum and tis- tions.21 Mupirocin use has been studied in and is efficacious sue concentrations of the antimicrobial if the duration of in children colonized with MRSA, but there are limited data the procedure exceeds two half-lives of the drug or there supporting its use perioperatively.24–30 However, there is is excessive blood loss during the procedure (Table 1). little reason to think that the impact and effect would be any Recommendations for selection of antimicrobial agents for different in children, so its use may be justified. Additional specific surgical procedures and alternative agents (e.g.,
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • Utility of the Digital Rectal Examination in the Emergency Department: a Review
    The Journal of Emergency Medicine, Vol. 43, No. 6, pp. 1196–1204, 2012 Published by Elsevier Inc. Printed in the USA 0736-4679/$ - see front matter http://dx.doi.org/10.1016/j.jemermed.2012.06.015 Clinical Reviews UTILITY OF THE DIGITAL RECTAL EXAMINATION IN THE EMERGENCY DEPARTMENT: A REVIEW Chad Kessler, MD, MHPE*† and Stephen J. Bauer, MD† *Department of Emergency Medicine, Jesse Brown VA Medical Center and †University of Illinois-Chicago College of Medicine, Chicago, Illinois Reprint Address: Chad Kessler, MD, MHPE, Department of Emergency Medicine, Jesse Brown Veterans Hospital, 820 S Damen Ave., M/C 111, Chicago, IL 60612 , Abstract—Background: The digital rectal examination abdominal pain and acute appendicitis. Stool obtained by (DRE) has been reflexively performed to evaluate common DRE doesn’t seem to increase the false-positive rate of chief complaints in the Emergency Department without FOBTs, and the DRE correlated moderately well with anal knowing its true utility in diagnosis. Objective: Medical lit- manometric measurements in determining anal sphincter erature databases were searched for the most relevant arti- tone. Published by Elsevier Inc. cles pertaining to: the utility of the DRE in evaluating abdominal pain and acute appendicitis, the false-positive , Keywords—digital rectal; utility; review; Emergency rate of fecal occult blood tests (FOBT) from stool obtained Department; evidence-based medicine by DRE or spontaneous passage, and the correlation be- tween DRE and anal manometry in determining anal tone. Discussion: Sixteen articles met our inclusion criteria; there INTRODUCTION were two for abdominal pain, five for appendicitis, six for anal tone, and three for fecal occult blood.
    [Show full text]
  • The Differences Between ICD-9 and ICD-10
    Preparing for the ICD-10 Code Set: Fact Sheet 2 October 1, 2015 Compliance Date Get the Facts to be Compliant Alert: The new ICD-10 compliance date is October 1, 2015. The Differences Between ICD-9 and ICD-10 This is the second fact sheet in a series and is focused on the differences between the ICD-9 and ICD-10 code sets. Collectively, the fact sheets will provide information, guidance, and checklists to assist you with understanding what you need to do to implement the ICD-10 code set. The ICD-10 code sets are not a simple update of the ICD-9 code set. The ICD-10 code sets have fundamental changes in structure and concepts that make them very different from ICD-9. Because of these differences, it is important to develop a preliminary understanding of the changes from ICD-9 to ICD-10. This basic understanding of the differences will then identify more detailed training that will be needed to appropriately use the ICD-10 code sets. In addition, seeing the differences between the code sets will raise awareness of the complexities of converting to the ICD-10 codes. Overall Comparisons of ICD-9 to ICD-10 Issues today with the ICD-9 diagnosis and procedure code sets are addressed in ICD-10. One concern today with ICD-9 is the lack of specificity of the information conveyed in the codes. For example, if a patient is seen for treatment of a burn on the right arm, the ICD-9 diagnosis code does not distinguish that the burn is on the right arm.
    [Show full text]
  • Approved Livestock Drug Registrations
    Livestock Drug Labels‐Approved and Provisional Status Firm: Product Name, Brand or Trademark Product Category Provisional ADEPTUS NUTRITION INC NIMBLE MEGA NUTRIENT (S&E RECEIVED) Physiological (Structure/Function) Provisional ADEPTUS NUTRITION INC NIMBLE ULTRA (S & E Received) Physiological (Structure/Function) Provisional ADEPTUS NUTRITION INC NIMBLE SUPREME (S & E Received) Physiological (Structure/Function) Approved ADEPTUS NUTRITION INC ADEPTUS WOUND AND SKIN SPRAY Topical Approved AFS DISTRIBUTING DURASOLE Topical Approved AGRI LABORATORIES LTD FERRRODEX 100 Injectable Approved AGRI LABORATORIES LTD VITAMIN E‐300 Injectable Approved AGRI LABORATORIES LTD PROPYLENE GLYCOL Physiological (Structure/Function) Approved AGRI LABORATORIES LTD IODINE WOUND SPRAY Topical Approved AGRI LABORATORIES LTD AGRI‐MECTIN (IVERMECTIN) INJECTION FOR CATTLE AND SWINE (RD) Restricted Drug‐/‐Wormer Approved AGRI LABORATORIES LTD AGRI‐MECTIN (IVERMECTIN) POUR‐ON FOR CATTLE (RD) Restricted Drug‐/‐Wormer Approved AGRI LABORATORIES LTD DEXTROSE 50% Injectable Approved AGRI LABORATORIES LTD PROHIBIT (LEVAMISOL HYDROCHLORIDE) SOLUBLE DRENCH POWDER (RD) Restricted Drug‐/‐Wormer Approved AGRI LABORATORIES LTD KAO‐PEC ANTI‐DIARRHEAL LIQUID Physiological (Structure/Function) Approved AGRI LABORATORIES LTD AGRIMYCIN 200 (OXYTETRACYCLINE) (CA RX RD) Restricted Drug‐/‐Injectable Approved AGRI LABORATORIES LTD VITAMIN E‐AD 300 INJECTABLE TOCOPHEROL WITH A+D Injectable Approved AGRI LABORATORIES LTD VITAMIN A D INJECTION Injectable Approved AGRI LABORATORIES LTD FORTIFIED
    [Show full text]
  • 28912 Oxoid FDA Cartridge Tables:1
    * Adapted in part from CLSI document M100-S23 (M02-A11) : “Disc diffusion supplemental tablesʼʼ Performance standards for antimicrobial susceptibility testing. The complete standard may be obtained from the Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19807. Test Cultures (zone diameters in mm) Antimicrobial Agent Disc Code Potency Resistant Intermediate Susceptible Amikacin AK 30 μg EnterobacteriaceaeK, P. aeruginosa, Acinetobacter spp., and Staphylococcus spp. ≤14 15-16 ≥17 Amoxycillin - Clavulanic Acid AMC 20/10 μg EnterobacteriaceaeE ≤13 14-17 ≥18 Staphylococcus spp.A,Q ≤19 — ≥20 Haemophilus spp.A,Y ≤19 — ≥20 AmpicillinC,n AMP 10 μg EnterobacteriaceaeE and Vibrio choleraef ≤13 14-16 ≥17 Staphylococcus spp.A,Q ≤28 — ≥29 Enterococcus spp.A,V,W,k,m ≤16 — ≥17 Haemophilus spp.Y ≤18 19-21 ≥22 Streptococcus spp. ß-Hemolytic GroupA,d — — ≥24 Ampicillin – Sulbactam SAM 10/10 μg EnterobacteriaceaeE, Acinetobacter spp., and Staphylococcus spp. ≤11 12-14 ≥15 Haemophilus spp.A,Y ≤19 — ≥20 Azithromycin AZM 15 μg Staphylococcus spp., Streptococcus spp Viridans Groupn, ß-Hemolytic Group, and S. pneumoniae) ≤13 14-17 ≥18 Neisseria meningitidisA,i — — ≥20 Haemophilus spp.A — — ≥12 Aztreonam ATM 30 μg EnterobacteriaceaeE ≤17 18-20 ≤21 P. aeruginosa ≤15 16-21 ≥22 Haemophilus spp.A — — ≥26 CAR 100 μg Carbenicillin Enterobacteriaceae ≤19 20-22 ≥23 Pseudomonas aeruginosaP ≤13 14-16 ≥17 CEC 30 μg Cefaclor Enterobacteriaceae and Staphylococcus spp. ≤14 15-17 ≥18 Haemophilus spp.Y ≤16 17-19 ≥20 MA 30 μg Cefamandole EnterobacteriaceaeD,E and Staphylococcus spp. ≤14 15-17 ≥18 CefazolinG KZ 30 μg Staphylococcus spp.
    [Show full text]
  • 12. What's Really New in Antibiotic Therapy Print
    What’s really new in antibiotic therapy? Martin J. Hug Freiburg University Medical Center EAHP Academy Seminars 20-21 September 2019 Newsweek, May 24-31 2019 Disclosures There are no conflicts of interest to declare EAHP Academy Seminars 20-21 September 2019 Antiinfectives and Resistance EAHP Academy Seminars 20-21 September 2019 Resistance of Klebsiella pneumoniae to Pip.-Taz. olates) EAHP Academy Seminars 20-21 September 2019 https://resistancemap.cddep.org/AntibioticResistance.php Multiresistant Pseudomonas Aeruginosa Combined resistance against at least three different types of antibiotics, 2017 EAHP Academy Seminars 20-21 September 2019 https://atlas.ecdc.europa.eu/public/index.aspx Distribution of ESBL producing Enterobacteriaceae EAHP Academy Seminars 20-21 September 2019 Rossolini GM. Global threat of Gram-negative antimicrobial resistance. 27th ECCMID, Vienna, 2017, IS07 Priority Pathogens Defined by the World Health Organisation Critical Priority High Priority Medium Priority Acinetobacter baumanii Enterococcus faecium Streptococcus pneumoniae carbapenem-resistant vancomycin-resistant penicillin-non-susceptible Pseudomonas aeruginosa Helicobacter pylori Haemophilus influenzae carbapenem-resistant clarithromycin-resistant ampicillin-resistant Enterobacteriaceae Salmonella species Shigella species carbapenem-resistant fluoroquinolone-resistant fluoroquinolone-resistant Staphylococcus aureus vancomycin or methicillin -resistant Campylobacter species fluoroquinolone-resistant Neisseria gonorrhoae 3rd gen. cephalosporin-resistant
    [Show full text]
  • Severe Sepsis and Septic Shock Antibiotic Guide
    Stanford Health Issue Date: 05/2017 Stanford Antimicrobial Safety and Sustainability Program Severe Sepsis and Septic Shock Antibiotic Guide Table 1: Antibiotic selection options for healthcare associated and/or immunocompromised patients • Healthcare associated: intravenous therapy, wound care, or intravenous chemotherapy within the prior 30 days, residence in a nursing home or other long-term care facility, hospitalization in an acute care hospital for two or more days within the prior 90 days, attendance at a hospital or hemodialysis clinic within the prior 30 days • Immunocompromised: Receiving chemotherapy, known systemic cancer not in remission, ANC <500, severe cell-mediated immune deficiency Table 2: Antibiotic selection options for community acquired, immunocompetent patients Table 3: Antibiotic selection options for patients with simple sepsis, community acquired, immunocompetent patients requiring hospitalization. Risk Factors for Select Organisms P. aeruginosa MRSA Invasive Candidiasis VRE (and other resistant GNR) Community acquired: • Known colonization with MDROs • Central venous catheter • Liver transplant • Prior IV antibiotics within 90 day • Recent MRSA infection • Broad-spectrum antibiotics • Known colonization • Known colonization with MDROs • Known MRSA colonization • + 1 of the following risk factors: • Prolonged broad antibacterial • Skin & Skin Structure and/or IV access site: ♦ Parenteral nutrition therapy Hospital acquired: ♦ Purulence ♦ Dialysis • Prolonged profound • Prior IV antibiotics within 90 days ♦ Abscess
    [Show full text]
  • Tube Feeding Using the Bolus Method | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Tube Feeding Using the Bolus Method This information will help teach you how to use the bolus method to feed yourself and take your medications through your percutaneous endoscopic gastrostomy (PEG), gastrostomy tube (GT), or nasogastric tube (NGT). About Tube Feeding Tube feeding is when you get your nutrients through a feeding tube if you aren’t able to get enough through eating and drinking, or if you can’t swallow safely. Nutrients provide energy and help you heal. The bolus method is a type of feeding where a syringe is used to send formula through your feeding tube. The syringe you’ll use is called a catheter syringe. A catheter syringe doesn’t have a needle. It has a hole with a plunger in it. You draw up formula through the hole in the syringe then push the formula into your feeding tube with the plunger. A bolus refers to 1 “meal” of formula. You may have a feeding tube with a legacy connector or an ENFit connector. In this resource, we’ll show images of both types of connectors. For more information about your feeding tube, including how to manage side effects, read Tube Feeding Troubleshooting Guide. Tube Feeding Using the Bolus Method 1/11 Tube Feeding Guidelines Formula: __________ Total cans per day: ____________________ (8 ounces each) Calories per day: __________ You can choose the times of your feedings, as long as you reach your daily nutritional goals. Write in the times you prefer or your doctor, advanced practice provider (APP), or clinical dietitian nutritionist recommends.
    [Show full text]
  • Antimicrobial Surgical Prophylaxis
    Antimicrobial Surgical Prophylaxis The antimicrobial surgical prophylaxis protocol establishes evidence-based standards for surgical prophylaxis at The Nebraska Medical Center. The protocol was adapted from the recently published consensus guidelines from the American Society of Health-System Pharmacists (ASHP), Society for Healthcare Epidemiology of America (SHEA), Infectious Disease Society of America (IDSA), and the Surgical Infection Society (SIS) and customized to Nebraska Medicine with the input of the Antimicrobial Stewardship Program in concert with the various surgical groups at the institution. The protocol established here-in will be implemented via standard order sets utilized within One Chart. Routine surgical prophylaxis and current and future surgical order sets are expected to conform to this guidance. Antimicrobial Surgical Prophylaxis Initiation Optimal timing: Within 60 minutes before surgical incision o Exceptions: Fluoroquinolones and vancomycin (within 120 minutes before surgical incision) Successful prophylaxis necessitates that the antimicrobial agent achieve serum and tissue concentrations above the MIC for probable organisms associated with the specific procedure type at the time of incision as well as for the duration of the procedure. Renal Dose Adjustment Guidance The following table can be utilized to determine if adjustments are needed to antimicrobial surgical prophylaxis for both pre-op and post-op dosing. Table 1 Renal Dosage Adjustment Dosing Regimen with Dosing Regimen with CrCl Dosing Regimen with
    [Show full text]
  • Product Monograph
    Product Monograph PrORB-CEFUROXIME Cefuroxime Axetil Tablets, USP 250 mg and 500 mg cefuroxime/tablet Antibiotic Orbus Pharma Inc. Date of Preparation: February 25, 2009 20 Konrad Crescent Markham, Ontario Control #: 117041 L3R8T4 1 Product Monograph PrORB-CEFUROXIME Cefuroxime Axetil Tablets, USP 250 mg and 500 mg cefuroxime/tablet Antibiotic Actions and Clinical Pharmacology Cefuroxime axetil is an orally active prodrug of cefuroxime. After oral administration, cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to release cefuroxime into the blood stream. Conversion to cefuroxime, the microbiologically active form, occurs rapidly. The inherent properties of cefuroxime are unaltered after its administration as cefuroxime axetil. Cefuroxime exerts its bactericidal effect by binding to an enzyme or enzymes referred to as penicillin-binding proteins (PBPs) involved in bacterial cell wall synthesis. This binding results in inhibition of bacterial cell wall synthesis and subsequent cell death. Specifically, cefuroxime shows high affinity for PBP 3, a primary target for cefuroxime in gram- negative organisms such as E. coli. Comparative Bioavailability Studies A two-way crossover, randomized, blinded, single-dose bioequivalence study was performed on 22 normal, healthy, non-smoking male subjects under fasting conditions. The rate and extent of absorption of cefuroxime axetil was measured and compared following a single oral dose (1 x 500 mg tablet)
    [Show full text]
  • The Efficacy of Cefmetazole Against Pyelonephritis Caused by Extended
    International Journal of Infectious Diseases 17 (2013) e159–e163 Contents lists available at SciVerse ScienceDirect International Journal of Infectious Diseases jou rnal homepage: www.elsevier.com/locate/ijid The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae a, b c d a,e Asako Doi *, Toshihiko Shimada , Sohei Harada , Kentaro Iwata , Toru Kamiya a Department of Infectious Diseases, Rakuwakai Otowa Hospital, Otowachinji-cho 2, Yamashina-ku, Kyoto, Japan b Department of General Internal Medicine, Nara City Hospital, Nara, Japan c Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Ota-ku, Tokyo, Japan d Division of Infectious Diseases, Kobe University Hospital, Chuo-ku, Kobe, Hyogo, Japan e Department of General Internal Medicine, Rakuwakai Otowa Hospital, Otowachinji-cho 2, Yamashina-ku, Kyoto, Japan A R T I C L E I N F O S U M M A R Y Article history: Objectives: Urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)- Received 3 April 2012 producing Enterobacteriaceae are on the increase. Although cefmetazole is stable in vitro against the Accepted 26 September 2012 hydrolyzing activity of ESBLs, no clinical study has ever evaluated its role in infections caused by these Corresponding Editor: William Cameron, organisms. We therefore evaluated the efficacy of cefmetazole compared to carbapenems against Ottawa, Canada pyelonephritis caused by ESBL-producing Enterobacteriaceae. Methods: A retrospective chart review was conducted at a tertiary care hospital from August 2008 to July Keywords: 2010. Chart reviews were done for patients with ESBL-producing organisms in urine identified in the Extended-spectrum beta-lactamase (ESBL) microbiology database.
    [Show full text]